Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention?

Journal of Neuroinflammation

Santiago Rivera²  Michel Khrestchatisky²  Gary L Wenk¹  Kevin Baranger²  Yannick Marchalant² 

[1] The Ohio State University, Psychology Department, Columbus, OH, USA;CNRS, NICN, UMR 7259, 13344, Marseille, France

关键词: prevention;    neurogenesis;    neuroinflammation;    cannabinoids;    Ageing;    Alzheimer's disease;   

Others  :  1212872
DOI  :  10.1186/1742-2094-9-10

 received in 2011-12-08, accepted in 2012-01-16,  发布年份 2012

【 摘 要 】

Background

Alzheimer's disease has become a growing socio-economical concern in developing countries where increased life expectancy is leading to large aged populations. While curing Alzheimer's disease or stopping its progression does not appear within reach in a foreseeable future, new therapies capable of delaying the pathogenesis would represent major breakthroughs.

Presentation of the hypothesis

The growing number of medical benefits of cannabinoids, such as their ability to regulate age-related processes like neuroinflammation, neurogenesis and memory, raise the question of their potential role as a preventive treatment of AD.

Testing the hypothesis

To test this hypothesis, epidemiological studies on long term, chronic cannabinoid users could enlighten us on the potential benefits of these compounds in normal and pathological ageing processes. Systematic pharmacological (and thus more mechanistic) investigations using animal models of Alzheimer's disease that have been developed would also allow a thorough investigation of the benefits of cannabinoid pharmacotherapy in the pathogenesis of Alzheimer's disease.

Implications of the hypothesis

The chronic administration of non-selective cannabinoids may delay the onset of cognitive deficits in AD patients; this will dramatically reduce the socio-economic burden of AD and improve the quality of life of the patients and their families.

【 授权许可】

   
2012 Marchalant et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, et al.: Inflammation and Alzheimer's disease. Neurobiol aging 2000, 21:383-421.
• [2]Pertwee RG: Pharmacological actions of cannabinoids. Handbook of experimental pharmacology 2005, 1-51.
• [3]Perry VH, Cunningham C, Holmes C: Systemic infections and inflammation affect chronic neurodegeneration. Nat rev Immunol 2007, 7:161-7.
• [4]Klegeris A, McGeer EG, McGeer PL: Therapeutic approaches to inflammation in neurodegenerative disease. Current opinion in neurology 2007, 20:351-7.
• [5]in t' Veld Ba, Ruitenberg a, Hofman a, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New Engl j med 2001, 345:1515-21.
• [6]Meinert CL, McCaffrey LD, Breitner JCS: Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers dement 2009, 5:93-104.
• [7]Hauss-Wegrzyniak B, Vraniak P, Wenk GL: The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol aging 1999, 20:305-13.
• [8]Britton GB, Rao KSJ: Cognitive aging and early diagnosis challenges in Alzheimer's disease. J Alzheimers dis : JAD 2011, 24(Suppl 2):153-9.
• [9]Németh B, Ledent C, Freund TF, Hájos N: CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2. Neuropharmacology 2008, 54:51-7.
• [10]Downer EJ: Cannabinoids and innate immunity: taking a toll on neuroinflammation. The Scientific World Journal 2011, 11:855-65.
• [11]Alger BE, Kim J: Supply and demand for endocannabinoids. Trends Neurosci 2011., 34
• [12]Mackie K: Cannabinoid receptors as therapeutic targets. Annu rev pharmacol toxicol 2006, 46:101-22.
• [13]Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S: Effects of endocannabinoid system modulation on cognitive and emotional behavior. Frontiers in behav neurosci 2011, 5:57.
• [14]Fowler CJ, Holt S, Nilsson O, Jonsson K-O, Tiger G, Jacobsson SOP: The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol biochem be 2005, 81:248-62.
• [15]Ashton JC, Glass M: The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration. Curr Neuropharmacol 2007, 5:73-80.
• [16]Marchalant Y, Brothers HM, Wenk GL: Inflammation and aging: can endocannabinoids help? Biomed Pharmacother 2008, 62:212-217.
• [17]Marchalant Y, Brothers HM, Wenk GL: Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain. Mol psych 2009, 14:1068-9.
• [18]Marchalant Y, Cerbai F, Brothers HM, Wenk GL: Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol Aging 2008, 29:1894-1901.
• [19]Marchalant Y, Rosi S, Wenk GL: Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience 2007, 144:1516-22.
• [20]Marchalant Y, Brothers HM, Norman GJ, Karelina K, DeVries a C, Wenk GL: Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiol Dis 2009, 34:300-307.
• [21]Malone DT, Hill MN, Rubino T: Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Brit j pharmacol 2010, 160:511-22.
• [22]Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM: Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 2005, 64:743-753.
• [23]McGowan E, Eriksen J, Hutton M: A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006, 22:281-9.
• [24]Morrissette Da, Parachikova A, Green KN, LaFerla FM: Relevance of transgenic mouse models to human Alzheimer disease. J biol chem 2009, 284:6033-7.
• [25]Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R: Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26:10129-40.
• [26]Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction. Neuron 2003, 39:409-421.